Sun-Novo(SH:688621) Ge Long Hui·2025-12-11 08:15Core Viewpoint - Sunshine Nuohua (688621.SH) is advancing its strategic layout in the field of novel nano-conjugated drugs and precise nano-delivery by investing 20 million yuan to increase its stake in Biling Biotechnology [1] Group 1: Investment and Stake Acquisition - The company plans to use its own funds to invest 20 million yuan to subscribe to an increase in registered capital of 8.2661 thousand yuan in Biling Biotechnology, resulting in a 2.0435% equity stake [1] Group 2: Company Overview - Biling Biotechnology, established in May 2021, focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - The company has formed a multidisciplinary R&D team covering biology, chemistry, materials, engineering, and nanotechnology [1] Group 3: Technological Advancements - Biling Biotechnology has developed three core technology platforms: nano-mediated conjugated drug technology platform, small molecule-small molecule self-assembly nano-technology platform, and continuous intelligent manufacturing platform for nano-drugs [1] - The company has successfully established a full-chain technology barrier for nano-drugs from R&D to production, utilizing proprietary high-throughput continuous manufacturing processes and equipment [1] Group 4: Innovation and Clinical Development - Biling Biotechnology aims to create breakthrough therapies that are "more effective, safer, more convenient, and more economical" through a four-dimensional integration of new materials, new technologies, new equipment, and new drugs [1] - The company has submitted over ten invention patents, with several granted in regions such as China, the US, Europe, and Japan; multiple drug candidates are accelerating towards clinical trials [1]